Shopping Cart 0
Cart Subtotal
USD 0

Albany Molecular Research Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Albany Molecular Research Inc (AMRI) is a contract research and manufacturing organization. Its service portfolio includes drug discovery and development, manufacturing of Active Pharmaceutical Ingredients (API); process scale up development of fine chemicals and aseptic filling services for preclinical, clinical and commercial projects; manufacture of drug product for new and generic drugs and project management services. The company serves pharmaceutical, agrochemical and other sectors including detergent and cosmetics industries. AMRI offers drug discovery and development services across various therapeutic categories including infectious diseases, neurodegenerative disorders, metabolic disorders, cardiovascular and oncology. It has presence in the US, Europe and Asia. AMRI is headquartered in Albany, New York, the US.

Albany Molecular Research Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Albany Molecular Research Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Albany Molecular Research Inc, Medical Devices Deals, 2012 to YTD 2018 11

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deal Details 14

Private Equity 14

Carlyle Group and GTCR Acquires Albany Molecular Research 14

Mandarin Capital Management Completes Sale Of 30% Stake In Euticals 16

Partnerships 17

Nemus Bioscience Enters into Agreement with Albany Molecular 17

Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 18

Albany Molecular Research Enters into Agreement with University at Albany 19

Nemus Bioscience Enters into Agreement with Albany Molecular Research 20

Albany Molecular Research Enters into Agreement with New York Center for Nanomedicine Research 21

Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 22

Albany Molecular Research Enters into Agreement with Icagen 23

Albany Molecular Research Enters into Co-Marketng Agreement with Multispan 24

Albany Molecular Research Enters into Agreement with Saneca Pharma 25

Albany Molecular Research Enters into Agreement with PerkinElmer 26

Albany Molecular Research Enters into Agreement with HarkerBIO 27

Albany Molecular Research Enters Into Smartsourcing Partnership With Codexis 28

Albany Molecular Enters Into An Agreement With Knopp Biosciences For Discovery Services 29

AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 30

Licensing Agreements 31

Denovo Biopharma Enters into Licensing Agreement with Albany Molecular Research 31

Chai Therapeutics Exercises Option For Licensing Agreement With Albany Molecular Research To Develop ALB 109564(a) 32

Albany Molecular Research Enters into Licensing Agreement with Broad Institute 33

Albany Molecular Research Enters into Licensing Agreement with Teewinot Life Sciences 34

Equity Offering 35

Albany Molecular Research Plans to Raise Funds in Public Offering 35

Albany Molecular Research to Raise Funds through Private Placement of Shares 36

Debt Offering 37

Albany Molecular Research Completes Private Placement Of Notes Due 2018 For USD 130 Million 37

Acquisition 39

Albany Molecular Research Acquires Euticals 39

Albany Molecular Research Acquires Gadea Grupo Farmaceutico 41

Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 42

Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 43

Albany Molecular Research Completes Acquisition of OSO BioPharma for USD110 Million 44

Emami Plans to Acquire 33% Stake in AMRI form Bengal Shrachi Housing Development 45

Albany Molecular Research Acquires Cedarburg Pharmaceuticals 46

Clave Mayor Sells 9.73% Stake In Gadea Grupo Farmaceutico 48

Albany Molecular Research Inc-Key Competitors 49

Albany Molecular Research Inc-Key Employees 50

Albany Molecular Research Inc-Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Recent Developments 53

Strategy And Business Planning 53

Apr 24, 2018: AMRI Expands NMR Spectroscopy Capabilities in Europe 53

Feb 22, 2018: AMRI to Expand Container Closure Integrity Testing Services (CCIT) into European Union 54

Dec 14, 2017: AMRI's SSCI Announces Plans to Expand Spectroscopy Capabilities 55

Financial Announcements 56

May 09, 2017: AMRI Announces First Quarter 2017 Results 56

Feb 21, 2017: AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook 57

Corporate Communications 60

Jun 11, 2018: Albany Molecular Research Appoints Prakash Pandian As Chief Information Officer 60

May 07, 2018: Steven Lichter joins AMRI as Senior Vice President, General Manager API 61

Apr 30, 2018: AMRI Names Diane Beno As Senior Vice President, Quality 62

Feb 21, 2018: AMRI Appoints Anthony L. Mattacchione to Senior Vice President and Chief Financial Officer 63

Jan 04, 2018: AMRI Names Michael Mulhern as Chief Executive Officer 64

Oct 30, 2017: AMRI Appoints Paul Feuerman as Senior Vice President, General Counsel and Head of Business Development 65

Oct 02, 2017: AMRI Names Joseph D. Sangregorio as Senior Vice President and Chief Human Resources Officer 66

Sep 12, 2017: AMRI Names Stephen Leonard as Senior Vice President Head of Global Operations 67

Legal and Regulatory 68

Sep 12, 2017: 3ST Research Files Litigation Alleging Fraud and Conversion of Inventors Intellectual Property Rights by Albany Molecular Research (AMRI) 68

Product News 69

Oct 18, 2017: AMRI's SSCI Adds Cobalt Light Systems Transmission Raman Spectrometer to Expand Vibrational Spectroscopy Services 69

Other Significant Developments 70

Nov 30, 2017: AMRI Doubles Bulk API Aseptic Manufacturing Capacity 70

Oct 12, 2017: AMRI Launches Stand-Alone Service; Expanding Solutions for Impurity Analysis and Toxicology Risk Assessment 71

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72


List Of Figure

List of Figures

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Albany Molecular Research Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Key Facts 2

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Albany Molecular Research Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Albany Molecular Research Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Albany Molecular Research Inc, Medical Devices Deals, 2012 to YTD 2018 11

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Carlyle Group and GTCR Acquires Albany Molecular Research 14

Mandarin Capital Management Completes Sale Of 30% Stake In Euticals 16

Nemus Bioscience Enters into Agreement with Albany Molecular 17

Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 18

Albany Molecular Research Enters into Agreement with University at Albany 19

Nemus Bioscience Enters into Agreement with Albany Molecular Research 20

Albany Molecular Research Enters into Agreement with New York Center for Nanomedicine Research 21

Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 22

Albany Molecular Research Enters into Agreement with Icagen 23

Albany Molecular Research Enters into Co-Marketng Agreement with Multispan 24

Albany Molecular Research Enters into Agreement with Saneca Pharma 25

Albany Molecular Research Enters into Agreement with PerkinElmer 26

Albany Molecular Research Enters into Agreement with HarkerBIO 27

Albany Molecular Research Enters Into Smartsourcing Partnership With Codexis 28

Albany Molecular Enters Into An Agreement With Knopp Biosciences For Discovery Services 29

AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 30

Denovo Biopharma Enters into Licensing Agreement with Albany Molecular Research 31

Chai Therapeutics Exercises Option For Licensing Agreement With Albany Molecular Research To Develop ALB 109564(a) 32

Albany Molecular Research Enters into Licensing Agreement with Broad Institute 33

Albany Molecular Research Enters into Licensing Agreement with Teewinot Life Sciences 34

Albany Molecular Research Plans to Raise Funds in Public Offering 35

Albany Molecular Research to Raise Funds through Private Placement of Shares 36

Albany Molecular Research Completes Private Placement Of Notes Due 2018 For USD 130 Million 37

Albany Molecular Research Acquires Euticals 39

Albany Molecular Research Acquires Gadea Grupo Farmaceutico 41

Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 42

Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 43

Albany Molecular Research Completes Acquisition of OSO BioPharma for USD110 Million 44

Emami Plans to Acquire 33% Stake in AMRI form Bengal Shrachi Housing Development 45

Albany Molecular Research Acquires Cedarburg Pharmaceuticals 46

Clave Mayor Sells 9.73% Stake In Gadea Grupo Farmaceutico 48

Albany Molecular Research Inc, Key Competitors 49

Albany Molecular Research Inc, Key Employees 50

Albany Molecular Research Inc, Subsidiaries 51

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Albany Molecular Research Inc (AMRI) is a contract research and manufacturing organization. Its service portfolio includes drug discovery and development, manufacturing of Active Pharmaceutical Ingredients (API); process scale up development of fine chemicals and aseptic filling services for preclinical, clinical and commercial projects; manufacture of drug product for new and generic drugs and project management services. The company serves pharmaceutical, agrochemical and other sectors including detergent and cosmetics industries. AMRI offers drug discovery and development services across various therapeutic categories including infectious diseases, neurodegenerative disorders, metabolic disorders, cardiovascular and oncology. It has presence in the US, Europe and Asia. AMRI is headquartered in Albany, New York, the US.

Albany Molecular Research Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Albany Molecular Research Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Albany Molecular Research Inc, Medical Devices Deals, 2012 to YTD 2018 11

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deal Details 14

Private Equity 14

Carlyle Group and GTCR Acquires Albany Molecular Research 14

Mandarin Capital Management Completes Sale Of 30% Stake In Euticals 16

Partnerships 17

Nemus Bioscience Enters into Agreement with Albany Molecular 17

Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 18

Albany Molecular Research Enters into Agreement with University at Albany 19

Nemus Bioscience Enters into Agreement with Albany Molecular Research 20

Albany Molecular Research Enters into Agreement with New York Center for Nanomedicine Research 21

Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 22

Albany Molecular Research Enters into Agreement with Icagen 23

Albany Molecular Research Enters into Co-Marketng Agreement with Multispan 24

Albany Molecular Research Enters into Agreement with Saneca Pharma 25

Albany Molecular Research Enters into Agreement with PerkinElmer 26

Albany Molecular Research Enters into Agreement with HarkerBIO 27

Albany Molecular Research Enters Into Smartsourcing Partnership With Codexis 28

Albany Molecular Enters Into An Agreement With Knopp Biosciences For Discovery Services 29

AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 30

Licensing Agreements 31

Denovo Biopharma Enters into Licensing Agreement with Albany Molecular Research 31

Chai Therapeutics Exercises Option For Licensing Agreement With Albany Molecular Research To Develop ALB 109564(a) 32

Albany Molecular Research Enters into Licensing Agreement with Broad Institute 33

Albany Molecular Research Enters into Licensing Agreement with Teewinot Life Sciences 34

Equity Offering 35

Albany Molecular Research Plans to Raise Funds in Public Offering 35

Albany Molecular Research to Raise Funds through Private Placement of Shares 36

Debt Offering 37

Albany Molecular Research Completes Private Placement Of Notes Due 2018 For USD 130 Million 37

Acquisition 39

Albany Molecular Research Acquires Euticals 39

Albany Molecular Research Acquires Gadea Grupo Farmaceutico 41

Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 42

Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 43

Albany Molecular Research Completes Acquisition of OSO BioPharma for USD110 Million 44

Emami Plans to Acquire 33% Stake in AMRI form Bengal Shrachi Housing Development 45

Albany Molecular Research Acquires Cedarburg Pharmaceuticals 46

Clave Mayor Sells 9.73% Stake In Gadea Grupo Farmaceutico 48

Albany Molecular Research Inc-Key Competitors 49

Albany Molecular Research Inc-Key Employees 50

Albany Molecular Research Inc-Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Recent Developments 53

Strategy And Business Planning 53

Apr 24, 2018: AMRI Expands NMR Spectroscopy Capabilities in Europe 53

Feb 22, 2018: AMRI to Expand Container Closure Integrity Testing Services (CCIT) into European Union 54

Dec 14, 2017: AMRI's SSCI Announces Plans to Expand Spectroscopy Capabilities 55

Financial Announcements 56

May 09, 2017: AMRI Announces First Quarter 2017 Results 56

Feb 21, 2017: AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook 57

Corporate Communications 60

Jun 11, 2018: Albany Molecular Research Appoints Prakash Pandian As Chief Information Officer 60

May 07, 2018: Steven Lichter joins AMRI as Senior Vice President, General Manager API 61

Apr 30, 2018: AMRI Names Diane Beno As Senior Vice President, Quality 62

Feb 21, 2018: AMRI Appoints Anthony L. Mattacchione to Senior Vice President and Chief Financial Officer 63

Jan 04, 2018: AMRI Names Michael Mulhern as Chief Executive Officer 64

Oct 30, 2017: AMRI Appoints Paul Feuerman as Senior Vice President, General Counsel and Head of Business Development 65

Oct 02, 2017: AMRI Names Joseph D. Sangregorio as Senior Vice President and Chief Human Resources Officer 66

Sep 12, 2017: AMRI Names Stephen Leonard as Senior Vice President Head of Global Operations 67

Legal and Regulatory 68

Sep 12, 2017: 3ST Research Files Litigation Alleging Fraud and Conversion of Inventors Intellectual Property Rights by Albany Molecular Research (AMRI) 68

Product News 69

Oct 18, 2017: AMRI's SSCI Adds Cobalt Light Systems Transmission Raman Spectrometer to Expand Vibrational Spectroscopy Services 69

Other Significant Developments 70

Nov 30, 2017: AMRI Doubles Bulk API Aseptic Manufacturing Capacity 70

Oct 12, 2017: AMRI Launches Stand-Alone Service; Expanding Solutions for Impurity Analysis and Toxicology Risk Assessment 71

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72


List Of Figure

List of Figures

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Albany Molecular Research Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Key Facts 2

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Albany Molecular Research Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Albany Molecular Research Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Albany Molecular Research Inc, Medical Devices Deals, 2012 to YTD 2018 11

Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Carlyle Group and GTCR Acquires Albany Molecular Research 14

Mandarin Capital Management Completes Sale Of 30% Stake In Euticals 16

Nemus Bioscience Enters into Agreement with Albany Molecular 17

Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 18

Albany Molecular Research Enters into Agreement with University at Albany 19

Nemus Bioscience Enters into Agreement with Albany Molecular Research 20

Albany Molecular Research Enters into Agreement with New York Center for Nanomedicine Research 21

Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 22

Albany Molecular Research Enters into Agreement with Icagen 23

Albany Molecular Research Enters into Co-Marketng Agreement with Multispan 24

Albany Molecular Research Enters into Agreement with Saneca Pharma 25

Albany Molecular Research Enters into Agreement with PerkinElmer 26

Albany Molecular Research Enters into Agreement with HarkerBIO 27

Albany Molecular Research Enters Into Smartsourcing Partnership With Codexis 28

Albany Molecular Enters Into An Agreement With Knopp Biosciences For Discovery Services 29

AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 30

Denovo Biopharma Enters into Licensing Agreement with Albany Molecular Research 31

Chai Therapeutics Exercises Option For Licensing Agreement With Albany Molecular Research To Develop ALB 109564(a) 32

Albany Molecular Research Enters into Licensing Agreement with Broad Institute 33

Albany Molecular Research Enters into Licensing Agreement with Teewinot Life Sciences 34

Albany Molecular Research Plans to Raise Funds in Public Offering 35

Albany Molecular Research to Raise Funds through Private Placement of Shares 36

Albany Molecular Research Completes Private Placement Of Notes Due 2018 For USD 130 Million 37

Albany Molecular Research Acquires Euticals 39

Albany Molecular Research Acquires Gadea Grupo Farmaceutico 41

Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 42

Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 43

Albany Molecular Research Completes Acquisition of OSO BioPharma for USD110 Million 44

Emami Plans to Acquire 33% Stake in AMRI form Bengal Shrachi Housing Development 45

Albany Molecular Research Acquires Cedarburg Pharmaceuticals 46

Clave Mayor Sells 9.73% Stake In Gadea Grupo Farmaceutico 48

Albany Molecular Research Inc, Key Competitors 49

Albany Molecular Research Inc, Key Employees 50

Albany Molecular Research Inc, Subsidiaries 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS